Stay Informed

Find out first how BGU is making an impact. Sign up for our e-newsletter.

Please leave this field empty
NewsArticleHead.jpg

Targeting Diabetes from the Negev

October 17, 2013

Bookmark and Share

When Andy David’s nine-year-old daughter was diagnosed with type 1 diabetes, the Israeli diplomat used his medical background to search for an unconventional treatment that would spare her from daily doses of insulin.

Eli Lewis in his Lab

Dr. Eli Lewis (center) with researchers in his lab at BGU

David, who is currently Israel’s consul general for the Pacific Northwest, soon learned about groundbreaking research being conducted by BGU's Dr. Eli Lewis and his team at the University's Clinical Islet Laboratory that shows great promise for patients in the early stages of type 1 diagnosis.

His daughter (unnamed her for security reasons) underwent eight weeks of transfusions of alpha 1, an anti-inflammatory drug generally used to treat emphysema.

“That was two and a half-years ago, and she has not had to have insulin,” said David, who is a non-practicing dentist and also has a degree in medical science.

He praised the researchers at BGU for their groundbreaking work. “Their goal is not to manage diabetes but to eliminate it,” he said.

Read more on The Jewish Week website >>